Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Adezmapimod
Cat. No.:
OB0225LY-0479
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Adezmapimod is a novel small molecule drug that is a MAPK inhibitor with anti-inflammatory and immunomodulatory properties.
Synonym:
PB 203580; RWJ 64809; SB203580; 152121-47-6; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; 4-[4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; 4-(4-(4-Fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine
CAS No.:
152121-47-6
Compound CID:
176155
Formula:
C21H16FN3OS
Formula Weight:
377.43
Specification
Relative Density:
1.42 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Adezmapimod can be used to study cell signaling pathways or play an important role in modeling inflammatory responses.
Library Information
Targets:
Serine/Threonine kinases
Receptors:
p38 MAPK
Pathways:
Autophagy; MAPK
Plate Number:
AOCL-7
Plate Location:
b8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 132.47 mM
Special Max Solubility:
1eq. HCl: 37.7 mg/mL
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (13.25 mM)
ALogP:
3.883
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
4
